GILD news

Gilead Sciences, Inc. · end-of-day data as of Oct 16, 2026

Gilead Sciences, Inc.

GILD · $194B

$156.19+21.5%last 60 sessions · close Oct 16, 2026

$115.00$157.3752 weeks

Buy · 28 analystsPT $159.20 +1.9%

P/E vs own—
P/E vs sector—
Target upside+1.9%
Off 52w high-0.7%
Insiders-$15.88M
FCF yield+6.8%
Earnings in13d
Trendbullish
Sector▲ +16.0%
RSI64
MA20×50↓ in ~19d
Volume1.4x
Support-2.1%
Resistance—

Last session

News0.00

Headlines

Gilead Sciences (GILD) Rises Higher Than Market: Key Facts
Zacks Investment Research · Oct 15, 2026
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
Zacks Investment Research · Oct 15, 2026
The Big 3: MRK, GILD, XOM
Schwab Network · Oct 15, 2026
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks Investment Research · Oct 15, 2026
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
Benzinga · Oct 14, 2026
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying
24/7 Wall Street · Oct 14, 2026
Gilead Sciences, Inc. $GILD Stock Acquired by RHS Financial LLC
Defense World · Oct 14, 2026
Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP?
Fool - Investing News · Oct 11, 2026
Head to Head Contrast: Gilead Sciences (NASDAQ:GILD) vs. GRAIL (NASDAQ:GRAL)
Defense World · Oct 11, 2026
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma
Fool - Investing News · Oct 10, 2026
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
Zacks Investment Research · Oct 9, 2026
Gilead (NASDAQ: GILD) CEO sells 15,000 shares under a preset plan
Defense World · Oct 4, 2026
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Zacks Investment Research · Oct 2, 2026
More Upside Awaits for Gilead Sciences Stock. Stay Invested.
Barrons · Oct 1, 2026
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Zacks Investment Research · Oct 1, 2026
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
Zacks Investment Research · Sep 30, 2026
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts
Defense World · Sep 26, 2026
Genetic discovery yields clues toward reversal of Alzheimer's brain damage
Reuters · Sep 25, 2026
NTHM's Index Rebalance Puts Thematic Rotation to Work
ETF Trends · Sep 25, 2026
Gilead Sciences, Inc. $GILD Stake Decreased by Envestnet Asset Management Inc.
Defense World · Sep 25, 2026
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
Zacks Investment Research · Sep 21, 2026
Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF
Business Wire · Sep 17, 2026
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Zacks Investment Research · Sep 17, 2026
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America
Zacks Investment Research · Sep 16, 2026
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
Business Wire · Sep 16, 2026
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits?
Fool - Investing News · Sep 15, 2026
Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances
MarketBeat · Sep 15, 2026
Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha · Sep 15, 2026
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
GuruFocus · Sep 15, 2026
Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean
Reuters · Sep 15, 2026

Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.